ACRP CCRA Certified Clinical Research Associate

According to ICH E6(R3), Good Clinical Practice (GCP) is an international ethical, scientific and quality standard for:

• AManufacturing pharmaceutical products
• BPlanning, conducting, recording and reporting clinical trials involving human participants
• CMarketing approved drugs to healthcare providers
• DRegulating the sale of medical devices

What is the PRIMARY purpose of informed consent in a clinical trial?

• ATo protect the sponsor from legal liability
• BTo ensure the subject voluntarily agrees to participate after understanding the trial's p…
• CTo fulfill a regulatory requirement with no direct impact on the subject
• DTo allow the investigator to enroll subjects more quickly

During a routine monitoring visit, a CRA discovers that the investigator has not been reporting adverse events within the protocol-specified timelines. The CRA should FIRST:

• AReport the finding to the IRB/IEC directly
• BDocument the finding and discuss it with the investigator to understand the cause and dev…
• CImmediately close the site to further enrollment
• DIgnore the issue if the adverse events are not serious

According to ICH GCP, who is ultimately responsible for the medical care of trial subjects at the investigational site?

• AThe clinical research coordinator
• BThe principal investigator
• CThe sponsor's medical monitor
• DThe Institutional Review Board

What document contains the clinical and nonclinical data about the investigational product that is relevant to the study of the product in human subjects?

• AThe case report form
• BThe Investigator's Brochure
• CThe monitoring plan
• DThe statistical analysis plan

A CRA is conducting source data verification (SDV) during a monitoring visit. SDV involves comparing:

• AThe protocol with the IRB approval letter
• BData recorded in the CRF/eCRF with original source documents at the site
• CThe investigator's CV with the delegation log
• DThe sponsor's budget with the site's financial records

According to ICH GCP, the IRB/IEC must review and approve the protocol and informed consent form BEFORE:

• AThe sponsor finalizes the study budget
• BThe first subject is enrolled at the site
• CThe CRA conducts the first monitoring visit
• DThe investigator submits their CV to the sponsor

What is a Serious Adverse Event (SAE) as defined by ICH guidelines?

• AAny untoward medical occurrence in a trial subject
• BAn adverse event that results in death, is life-threatening, requires hospitalization or…
• CAn adverse event that is expected based on the Investigator's Brochure
• DAn adverse event that is mild in severity and self-limiting

The delegation log at a clinical trial site serves to:

• ATrack patient visit schedules throughout the trial
• BDocument all individuals authorized by the PI to perform trial-related tasks and their sp…
• CRecord the financial agreements between the sponsor and site
• DList the equipment calibration dates for all lab instruments

According to ICH GCP, the sponsor is responsible for implementing and maintaining quality assurance and quality control systems with written SOPs to ensure that trials are conducted and data are generated according to:

• AThe sponsor's marketing plan
• BThe protocol, GCP, and applicable regulatory requirements
• CThe site's internal operating procedures only
• DThe investigator's personal preferences

During a monitoring visit, the CRA finds that the investigator has delegated the informed consent process to an unqualified research assistant. The CRA should:

• AAccept this delegation since the investigator signed the delegation log
• BDocument the finding as a protocol deviation and discuss the requirement that only qualif…
• CIgnore the issue because the consent forms are properly signed
• DContact the IRB directly without informing the investigator

The Declaration of Helsinki is primarily concerned with:

• AStandardizing laboratory testing procedures across countries
• BEthical principles for medical research involving human subjects
• CEstablishing drug pricing guidelines internationally
• DDefining marketing approval pathways for new drugs

What is the purpose of the Investigator Site File (ISF) or regulatory binder?

• ATo store the sponsor's marketing materials for the investigational product
• BTo maintain all essential documents at the site that individually and collectively permit…
• CTo hold only the signed informed consent forms
• DTo store the site's financial records for tax purposes

According to ICH GCP, investigational products must be manufactured, handled, and stored in accordance with applicable Good Manufacturing Practice (GMP) and should be used in accordance with:

• AThe investigator's clinical experience only
• BThe approved protocol
• CThe pharmacy's standard dispensing procedures
• DThe subject's personal preference

A CRA discovers during a monitoring visit that the site has not maintained temperature logs for the investigational product refrigerator for the past two months. This finding is BEST classified as:

• AA minor administrative oversight that requires no action
• BA protocol deviation related to investigational product storage that requires documentati…
• CAn adverse event that must be reported to the IRB
• DA financial discrepancy between the sponsor and site

ICH E2A defines an unexpected adverse drug reaction as one whose nature or severity is:

• ANot consistent with the applicable product information in the Investigator's Brochure
• BMore severe than what the subject expected
• CNot reported within 24 hours of occurrence
• DNot observed in preclinical animal studies

During a site initiation visit (SIV), the CRA should ensure all of the following EXCEPT:

• AThe investigator and study team are trained on the protocol and study procedures
• BIRB/IEC approval has been obtained and documented
• CAll subjects have been screened and enrolled
• DThe investigational product has been received and stored properly

According to ICH GCP, the sponsor should ensure that a trial is adequately monitored. The determination of the extent and nature of monitoring should be based on:

• AThe available monitoring budget only
• BConsiderations such as the objective, purpose, design, complexity, blinding, size, and en…
• CThe investigator's preference for monitoring frequency
• DThe number of CRAs available at the sponsor's CRO

What is the PRIMARY difference between a protocol deviation and a protocol violation?

• AThere is no difference; the terms are interchangeable
• BA deviation is any departure from the protocol, while a violation is a deviation that may…
• CA deviation applies to the sponsor while a violation applies to the investigator
• DA deviation is documented while a violation is not

A subject in a clinical trial wishes to withdraw their consent and stop participating. According to ICH GCP, the subject:

• AMust provide a written reason for withdrawal before it is accepted
• BMay withdraw at any time without penalty or loss of benefits to which they are otherwise…
• CCan only withdraw with the investigator's approval
• DMust complete the current treatment cycle before withdrawal is effective

According to ICH GCP, the investigator should report to the sponsor all serious adverse events immediately, EXCEPT for those that:

• AOccur in elderly subjects
• BThe protocol or IB identifies as not requiring immediate reporting
• CAre reported by the subject verbally rather than in writing
• DOccur during the screening period before randomization

What is the purpose of an audit in a clinical trial setting?

• ATo help the investigator recruit more subjects
• BTo provide a systematic and independent examination of trial-related activities and docum…
• CTo negotiate the site's financial contract with the sponsor
• DTo train new CRAs on monitoring techniques

A CRA reviews the investigational product accountability records and notices a discrepancy between the number of doses shipped and the number dispensed plus returned. The CRA should:

• AIgnore the discrepancy if it is only one or two doses
• BDocument the discrepancy and investigate the cause by reconciling shipping records, dispe…
• CAssume the site destroyed the missing doses per protocol
• DWait until the next monitoring visit to address the issue

ICH E8 (General Considerations for Clinical Trials) describes the phases of clinical development. Phase III trials are primarily designed to:

• ADetermine the maximum tolerated dose in healthy volunteers
• BConfirm therapeutic benefit and safety in a larger patient population to support regulato…
• CStudy the drug's pharmacokinetic profile in a small group
• DEvaluate the drug's manufacturing process

According to ICH GCP, the sponsor should expedite the reporting of a SUSAR (Suspected Unexpected Serious Adverse Reaction) to all concerned investigators and regulatory authorities. Fatal or life-threatening SUSARs must be reported within:

• A30 calendar days
• B15 calendar days
• C7 calendar days, with a follow-up within an additional 8 days
• D24 hours

What is the PRIMARY purpose of randomization in a clinical trial?

• ATo ensure all subjects receive the investigational product
• BTo minimize selection bias and create comparable treatment groups
• CTo determine the appropriate dose for each subject
• DTo fulfill a regulatory requirement with no scientific benefit

A CRA arrives at a site and learns that the principal investigator has left the practice without a replacement PI being appointed. The CRA should:

• AContinue monitoring as usual since the research staff can manage the trial
• BNotify the sponsor immediately and ensure enrollment is stopped until a qualified replace…
• CAppoint the clinical research coordinator as the new PI
• DClose the site without notifying the sponsor

According to ICH GCP, essential documents should be retained for a minimum period of:

• A1 year after study completion
• BThe period applicable regulations require, or until the sponsor says the records are no l…
• C5 years after the last subject's last visit
• DUntil the drug is approved and marketed

A clinical trial site has a subject who meets an important protocol-defined stopping rule. The investigator wants to continue treatment because the subject is responding well. The CRA should advise the investigator to:

• AContinue treatment since clinical judgment should override protocol rules
• BFollow the protocol-defined stopping rule because deviating from the protocol without a p…
• CLet the subject decide whether to continue
• DIgnore the stopping rule because it only applies to safety events

What is blinding (masking) in a clinical trial?

• AHiding the trial results from the public until publication
• BA procedure in which one or more parties to the trial are kept unaware of the treatment a…
• CRemoving the sponsor's name from the protocol
• DEncrypting the clinical trial database

A CRA discovers that a site has been using an outdated version of the informed consent form after a protocol amendment. What is the MOST appropriate action?

• ADo nothing since the old consent form covers the original study procedures
• BDocument the finding, ensure the site begins using the current version, and determine whe…
• CDestroy all copies of the outdated consent form
• DReport the site to the regulatory authority immediately

According to ICH GCP, the sponsor should provide insurance or indemnification to cover the trial subjects against:

• AAll medical expenses during the trial regardless of causation
• BClaims arising from trial participation, including treatment of trial-related injuries
• CLost wages due to time spent at study visits
• DCosts of childcare during study visits

What is a case report form (CRF) used for in a clinical trial?

• ATo report the trial results to the public
• BTo record all protocol-required information for each trial subject to be reported to the…
• CTo document the investigator's academic publications
• DTo submit the drug application to regulatory authorities

A CRA identifies that a subject was enrolled in a trial despite not meeting the inclusion criteria. This is an example of:

• AAn adverse event
• BA protocol deviation involving eligibility criteria
• CNormal clinical trial variability
• DAn investigator's professional judgment call

According to ICH GCP, an IRB/IEC should include members who collectively have the qualifications and experience to:

• AManage the financial aspects of clinical trials
• BReview and evaluate the science, medical aspects, and ethics of proposed trials to ensure…
• CRecruit subjects for clinical trials
• DManufacture the investigational product

During a close-out visit, the CRA should verify all of the following EXCEPT:

• AAll CRFs are completed and outstanding queries are resolved
• BThe site's plans for future enrollment in new trials
• CInvestigational product has been returned or destroyed with proper documentation
• DEssential documents are complete and filed properly for long-term retention

ICH E9 (Statistical Principles for Clinical Trials) describes the intention-to-treat (ITT) principle. ITT analysis includes:

• AOnly subjects who completed the full treatment protocol
• BAll randomized subjects in the groups to which they were randomly assigned, regardless of…
• COnly subjects who had no adverse events during the trial
• DOnly subjects at the top-enrolling sites